Cyclacel Pharmaceuticals (CYCC) Earns News Sentiment Score of 0.17
News articles about Cyclacel Pharmaceuticals (NASDAQ:CYCC) have trended somewhat positive on Wednesday, according to Accern. The research group identifies negative and positive press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Cyclacel Pharmaceuticals earned a news sentiment score of 0.17 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 46.8384434611365 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Here are some of the news stories that may have impacted Accern’s analysis:
- Definitive Proof this stock will never make you disappointed:- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) – The Stock Street (press release) (thestreetpoint.com)
- Hot Stock under Consideration: Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) – Alpha Beta Stock (alphabetastock.com)
- Focus on Unusual Volume Activity Stock – Cyclacel Pharmaceuticals, Inc. (CYCC) – Wall Street Morning (wallstreetmorning.com)
- On Deck Capital, Inc. (ONDK) Is At $5.01 Formed Wedge; Shorts at Cyclacel Pharmaceuticals (CYCC) Raised By 5.19% – Hill Country Times (hillcountrytimes.com)
Shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC) opened at $2.00 on Wednesday. Cyclacel Pharmaceuticals has a fifty-two week low of $1.50 and a fifty-two week high of $10.90.
About Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals, Inc operates in the field of cell cycle biology. The Company has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase (CDK) inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor receptor (AK/VEGFR) inhibitors.
Receive News & Stock Ratings for Cyclacel Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.